Insider Selling: MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Sells $77,019.90 in Stock

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov sold 55,410 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total value of $77,019.90. Following the transaction, the chief executive officer now directly owns 1,105,790 shares of the company’s stock, valued at approximately $1,537,048.10. This represents a 4.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

MIRA Pharmaceuticals Stock Performance

MIRA Pharmaceuticals stock opened at $1.29 on Friday. MIRA Pharmaceuticals, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $5.01. The company has a market capitalization of $21.36 million, a P/E ratio of -2.30 and a beta of 3.09. The stock has a 50-day simple moving average of $1.34 and a 200-day simple moving average of $1.33.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MIRA shares. Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a research report on Monday, September 30th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW raised MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Ascendiant Capital Markets began coverage on MIRA Pharmaceuticals in a research report on Monday, August 5th. They set a “buy” rating and a $11.00 price objective for the company.

Institutional Trading of MIRA Pharmaceuticals

A hedge fund recently raised its stake in MIRA Pharmaceuticals stock. Virtu Financial LLC raised its stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 330.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 63,055 shares of the company’s stock after acquiring an additional 48,397 shares during the period. Virtu Financial LLC owned approximately 0.43% of MIRA Pharmaceuticals worth $69,000 as of its most recent SEC filing. Institutional investors and hedge funds own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.